Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance.
Aids Research And Therapy
Wolf, Eva E; Boesecke, Christoph C; Balogh, Annamaria A; Bidner, Helen H; Cordes, Christiane C; Heiken, Hans H; Krznaric, Ivanka I; Kümmerle, Tim T; Stellbrink, Hans-Jürgen HJ; Schneider, Jochen J; Spinner, Christoph D CD; ,
Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.
Antimicrobial Agents And Chemotherapy
Doualla-Bell, Florence F; Avalos, Ava A; Gaolathe, Tendani T; Mine, Madisa M; Gaseitsiwe, Simani S; Ndwapi, Ndwapi N; Novitsky, Vladimir A VA; Brenner, Bluma B; Oliveira, Maureen M; Moisi, Daniella D; Moffat, Howard H; Thior, Ibou I; Essex, Max M; Wainberg, Mark A MA
R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen.
Antimicrobial Agents And Chemotherapy
Masquelier, Bernard B; Droz, Cecile C; Dary, Martin M; Perronne, Christian C; Ferré, Virginie V; Spire, Bruno B; Descamps, Diane D; Raffi, François F; Brun-Vézinet, Françoise F; Chêne, Geneviève G; ,